Abbott presents HUMIRA® (adalimumab) Phase 3 study results
7 November 2011 | By Abbott
In ABILITY-1 Study Presented at ACR, More than Twice as Many Patients Treated with HUMIRA Met Primary Endpoint Compared to Placebo...
List view / Grid view
News
Interim data for Merck’s VICTRELIS™ (boceprevir) in prior null responder patients with Chronic Hepatitis C genotype 1 to be presented
5 November 2011 | By Merck
PROVIDE study results...
Treatment with Enbrel® (etanercept) shows significant and sustained clinical benefits in Rheumatoid Arthritis (RA) patients with moderately active disease
5 November 2011 | By Pfizer
PRESERVE trial results...
Positive five-year data showing effect of Viread(R) on liver fibrosis and cirrhosis caused by Chronic Hepatitis B
5 November 2011 | By
New long-term data show no development of resistance...
Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial
5 November 2011 | By Amgen
Positive data of the pivotal Phase 3 fracture trial...
Abbott announces new long-term data evaluating sse of HUMIRA® (Adalimumab) for patients with long-standing moderate to severe Rheumatoid Arthritis and for patients with early moderate to severe RA
5 November 2011 | By Abbott
PREMIER Eight-Year and DE019 10-Year Data Presented at ACR 2011...
GlaxoSmithKline reaches agreement in principle to resolve multiple investigations with US Government
3 November 2011 | By GlaxoSmithKline
$3 billion settlement covered by existing legal provisions...
ASLAN Pharmaceuticals and Bristol-Myers Squibb enter innovative partnership
3 November 2011 | By Bristol-Myers Squibb Company
Innovative strategic partnership to license and develop investigational oncology compound...
Abbott to present new data for key vascular products at TCT 2011
3 November 2011 | By Abbott
Abbott announced the company's schedule of key data presentations at the 23rd annual TCT scientific symposium...
Raman seminar at the Natural History Museum
3 November 2011 | By Renishaw
Raman spectroscopy came under the spotlight recently at the Natural History Museum in London...
Lilly CEO says appropriate assessment of both benefits and risks critical in regulatory process
2 November 2011 | By Eli Lilly and Company
John Lechleiter calls for balanced decision-making...
Sanofi tops Pfizer as number one for global pharma sales
1 November 2011 | By College Hill
Sanofi is expected to take the top spot amongst the world’s pharmaceuticals manufacturers in 2012...
Daiichi Sankyo establishes new vaccine research unit in Japan
1 November 2011 | By Daiichi Sankyo
Daiichi Sankyo has established a new Japanese vaccine research unit to be located in its Kasai R&D Center...
Richard Daniell appointed as Managing Director of Teva UK Limited
Teva UK Limited has announced that Richard Daniell has been appointed as Managing Director, responsible for all Teva’s commercial activities in the UK.
Abbott receives U.S. FDA approval for next-generation XIENCE PRIME™ Drug Eluting Stent
1 November 2011 | By Abbott
FDA approval for the next-generation XIENCE PRIME™ Drug Eluting System...
